Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 28-Day Study of GAL-101 in Participants With Mild to Moderate Alzheimer's Disease

NCT07789873 is registered in ClinicalTrials.gov with Galimedix Therapeutics Inc as lead sponsor.

NCT NCT07789873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07789873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 28-Day Study of GAL-101 in Participants With Mild to Moderate Alzheimer's Disease
Lead sponsor
Galimedix Therapeutics Inc
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 28, 2027
Completion date
July 31, 2028
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

mild to moderate alzheimer's disease